Anti-interleukin-5 therapy in patients with severe asthma: from clinical trials to clinical practice
- 14 February 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet. Respiratory Medicine
- Vol. 8 (5), 425-427
- https://doi.org/10.1016/s2213-2600(20)30051-5
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Placebo Effects in Clinical Trials Evaluating Patients with Uncontrolled Persistent AsthmaAnnals of the American Thoracic Society, 2019
- Randomised controlled trials in severe asthma: selection by phenotype or stereotypeEuropean Respiratory Journal, 2018
- Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent AsthmaJAMA, 2018
- Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studiesThe Lancet Respiratory Medicine, 2018
- Co‐morbidities in severe asthma: Clinical impact and managementRespirology, 2017
- A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthmaThe American Journal of Emergency Medicine, 2014
- Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trialThe Lancet. Respiratory Medicine, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthmaJournal of Allergy and Clinical Immunology, 2010